# BioNTech corporate developments and oncology expansion > Live situation record from CLSTR: https://clstr.news/situations/biontech-corporate-developments-and-oncology-expansion > Updated: 2026-10-06T21:08:10.000Z. Sources: 3. Developments: 2. BioNTech CEO Ugur Sahin executed multiple stock sales in early September, selling 149,500 shares at prices between approximately $96.31 and $103.52 per share. These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, reducing his direct holdings to approximately 688,209 shares. During this period, BMO Capital downgraded the company from ‘Outperform’ to ‘Market Perform,’ lowering the price target from $128 to $105. Analysts pointed to the erosion of the Comirnaty business and a lack of de-risking data for the antibody candidate pumitamig before 2028. Subsequently, BioNTech reported an expansion of its oncology portfolio, moving beyond COVID-19 vaccines. The company currently has over 25 phase 2 and phase 3 cancer trials underway, with a goal of having 15 phase 3 trials active by the end of 2026. These efforts focus on treatments such as pumitamig for various solid tumors, including lung, breast, gastric, and kidney cancers. ## Timeline ### 2026-10-06: BioNTech expands oncology pipeline amid various corporate insider stock sales BioNTech expands its oncology pipeline with over 25 late-stage trials, while executives at Rubrik, SiTime, and SiBone conduct various insider stock sales. 2 sources. https://clstr.news/cluster/biontech-expands-oncology-pipeline-amid-various-corporate-insider-stock-sales ### 2026-09-11: BioNTech CEO Ugur Sahin sells 149,500 shares in September BioNTech CEO Ugur Sahin sold 149,500 shares in early September via a pre-arranged trading plan, amid a BMO Capital downgrade of the stock due to pipeline and revenue concerns. 2 sources. https://clstr.news/cluster/biontech-ceo-ugur-sahin-sells-149500-shares-in-september --- Cite as: BioNTech corporate developments and oncology expansion. CLSTR, https://clstr.news/situations/biontech-corporate-developments-and-oncology-expansion